Chronic kidney disease after nephrectomy in patients with renal cortical tumours

a retrospective cohort study

William C. Huang, Andrew S. Levey, Angel M. Serio, Mark Snyder, Andrew J. Vickers, Ganesh V. Raj, Peter T. Scardino, Paul Russo

Research output: Contribution to journalArticle

1158 Citations (Scopus)

Abstract

Background: Chronic kidney disease is a graded and independent risk factor for substantial comorbidity and death. We aimed to examine new onset of chronic kidney disease in patients with small, renal cortical tumours undergoing radical or partial nephrectomy. Methods: We did a retrospective cohort study of 662 patients with a normal concentration of serum creatinine and two healthy kidneys undergoing elective partial or radical nephrectomy for a solitary, renal cortical tumour (≤4 cm) between 1989 and 2005 at a referral cancer centre. Glomerular filtration rate (GFR) was estimated with the abbreviated Modification in Diet and Renal Disease Study equation. Separate analysis was undertaken, with chronic kidney disease defined as GFR lower than 60 mL/min per 1·73 m2 and GFR lower than 45 mL/min per 1·73 m2. Findings: 171 (26%) patients had pre-existing chronic kidney disease before surgery. After surgery, the 3-year probability of freedom from new onset of GFR lower than 60 mL/min per 1·73 m2 was 80% (95% CI 73-85) after partial nephrectomy and 35% (28-43; p<0·0001) after radical nephrectomy; corresponding values for GFRs lower than 45 mL/min per 1·73 m2 were 95% (91-98) and 64% (56-70; p<0·0001), respectively. Multivariable analysis showed that radical nephrectomy remained an independent risk factor for patients developing new onset of GFR lower than 60 mL/min per 1·73 m2 (hazard ratio 3·82 [95% CI 2·75-5·32]) and 45 mL/min per 1·73 m2 (11·8 [6·24-22·4]; both p<0·0001). Interpretation: Because the baseline kidney function of patients with renal cortical tumours is lower than previously thought, accurate assessment of kidney function is essential before surgery. Radical nephrectomy is a significant risk factor for the development of chronic kidney disease and might no longer be regarded as the gold standard treatment for small, renal cortical tumours.

Original languageEnglish (US)
Pages (from-to)735-740
Number of pages6
JournalLancet Oncology
Volume7
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Nephrectomy
Chronic Renal Insufficiency
Cohort Studies
Retrospective Studies
Kidney
Glomerular Filtration Rate
Neoplasms
Diet Therapy
Comorbidity
Creatinine
Referral and Consultation
Serum

ASJC Scopus subject areas

  • Oncology

Cite this

Chronic kidney disease after nephrectomy in patients with renal cortical tumours : a retrospective cohort study. / Huang, William C.; Levey, Andrew S.; Serio, Angel M.; Snyder, Mark; Vickers, Andrew J.; Raj, Ganesh V.; Scardino, Peter T.; Russo, Paul.

In: Lancet Oncology, Vol. 7, No. 9, 09.2006, p. 735-740.

Research output: Contribution to journalArticle

Huang, WC, Levey, AS, Serio, AM, Snyder, M, Vickers, AJ, Raj, GV, Scardino, PT & Russo, P 2006, 'Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study', Lancet Oncology, vol. 7, no. 9, pp. 735-740. https://doi.org/10.1016/S1470-2045(06)70803-8
Huang, William C. ; Levey, Andrew S. ; Serio, Angel M. ; Snyder, Mark ; Vickers, Andrew J. ; Raj, Ganesh V. ; Scardino, Peter T. ; Russo, Paul. / Chronic kidney disease after nephrectomy in patients with renal cortical tumours : a retrospective cohort study. In: Lancet Oncology. 2006 ; Vol. 7, No. 9. pp. 735-740.
@article{7f007c56e13b47669c691434a584c25e,
title = "Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study",
abstract = "Background: Chronic kidney disease is a graded and independent risk factor for substantial comorbidity and death. We aimed to examine new onset of chronic kidney disease in patients with small, renal cortical tumours undergoing radical or partial nephrectomy. Methods: We did a retrospective cohort study of 662 patients with a normal concentration of serum creatinine and two healthy kidneys undergoing elective partial or radical nephrectomy for a solitary, renal cortical tumour (≤4 cm) between 1989 and 2005 at a referral cancer centre. Glomerular filtration rate (GFR) was estimated with the abbreviated Modification in Diet and Renal Disease Study equation. Separate analysis was undertaken, with chronic kidney disease defined as GFR lower than 60 mL/min per 1·73 m2 and GFR lower than 45 mL/min per 1·73 m2. Findings: 171 (26{\%}) patients had pre-existing chronic kidney disease before surgery. After surgery, the 3-year probability of freedom from new onset of GFR lower than 60 mL/min per 1·73 m2 was 80{\%} (95{\%} CI 73-85) after partial nephrectomy and 35{\%} (28-43; p<0·0001) after radical nephrectomy; corresponding values for GFRs lower than 45 mL/min per 1·73 m2 were 95{\%} (91-98) and 64{\%} (56-70; p<0·0001), respectively. Multivariable analysis showed that radical nephrectomy remained an independent risk factor for patients developing new onset of GFR lower than 60 mL/min per 1·73 m2 (hazard ratio 3·82 [95{\%} CI 2·75-5·32]) and 45 mL/min per 1·73 m2 (11·8 [6·24-22·4]; both p<0·0001). Interpretation: Because the baseline kidney function of patients with renal cortical tumours is lower than previously thought, accurate assessment of kidney function is essential before surgery. Radical nephrectomy is a significant risk factor for the development of chronic kidney disease and might no longer be regarded as the gold standard treatment for small, renal cortical tumours.",
author = "Huang, {William C.} and Levey, {Andrew S.} and Serio, {Angel M.} and Mark Snyder and Vickers, {Andrew J.} and Raj, {Ganesh V.} and Scardino, {Peter T.} and Paul Russo",
year = "2006",
month = "9",
doi = "10.1016/S1470-2045(06)70803-8",
language = "English (US)",
volume = "7",
pages = "735--740",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - Chronic kidney disease after nephrectomy in patients with renal cortical tumours

T2 - a retrospective cohort study

AU - Huang, William C.

AU - Levey, Andrew S.

AU - Serio, Angel M.

AU - Snyder, Mark

AU - Vickers, Andrew J.

AU - Raj, Ganesh V.

AU - Scardino, Peter T.

AU - Russo, Paul

PY - 2006/9

Y1 - 2006/9

N2 - Background: Chronic kidney disease is a graded and independent risk factor for substantial comorbidity and death. We aimed to examine new onset of chronic kidney disease in patients with small, renal cortical tumours undergoing radical or partial nephrectomy. Methods: We did a retrospective cohort study of 662 patients with a normal concentration of serum creatinine and two healthy kidneys undergoing elective partial or radical nephrectomy for a solitary, renal cortical tumour (≤4 cm) between 1989 and 2005 at a referral cancer centre. Glomerular filtration rate (GFR) was estimated with the abbreviated Modification in Diet and Renal Disease Study equation. Separate analysis was undertaken, with chronic kidney disease defined as GFR lower than 60 mL/min per 1·73 m2 and GFR lower than 45 mL/min per 1·73 m2. Findings: 171 (26%) patients had pre-existing chronic kidney disease before surgery. After surgery, the 3-year probability of freedom from new onset of GFR lower than 60 mL/min per 1·73 m2 was 80% (95% CI 73-85) after partial nephrectomy and 35% (28-43; p<0·0001) after radical nephrectomy; corresponding values for GFRs lower than 45 mL/min per 1·73 m2 were 95% (91-98) and 64% (56-70; p<0·0001), respectively. Multivariable analysis showed that radical nephrectomy remained an independent risk factor for patients developing new onset of GFR lower than 60 mL/min per 1·73 m2 (hazard ratio 3·82 [95% CI 2·75-5·32]) and 45 mL/min per 1·73 m2 (11·8 [6·24-22·4]; both p<0·0001). Interpretation: Because the baseline kidney function of patients with renal cortical tumours is lower than previously thought, accurate assessment of kidney function is essential before surgery. Radical nephrectomy is a significant risk factor for the development of chronic kidney disease and might no longer be regarded as the gold standard treatment for small, renal cortical tumours.

AB - Background: Chronic kidney disease is a graded and independent risk factor for substantial comorbidity and death. We aimed to examine new onset of chronic kidney disease in patients with small, renal cortical tumours undergoing radical or partial nephrectomy. Methods: We did a retrospective cohort study of 662 patients with a normal concentration of serum creatinine and two healthy kidneys undergoing elective partial or radical nephrectomy for a solitary, renal cortical tumour (≤4 cm) between 1989 and 2005 at a referral cancer centre. Glomerular filtration rate (GFR) was estimated with the abbreviated Modification in Diet and Renal Disease Study equation. Separate analysis was undertaken, with chronic kidney disease defined as GFR lower than 60 mL/min per 1·73 m2 and GFR lower than 45 mL/min per 1·73 m2. Findings: 171 (26%) patients had pre-existing chronic kidney disease before surgery. After surgery, the 3-year probability of freedom from new onset of GFR lower than 60 mL/min per 1·73 m2 was 80% (95% CI 73-85) after partial nephrectomy and 35% (28-43; p<0·0001) after radical nephrectomy; corresponding values for GFRs lower than 45 mL/min per 1·73 m2 were 95% (91-98) and 64% (56-70; p<0·0001), respectively. Multivariable analysis showed that radical nephrectomy remained an independent risk factor for patients developing new onset of GFR lower than 60 mL/min per 1·73 m2 (hazard ratio 3·82 [95% CI 2·75-5·32]) and 45 mL/min per 1·73 m2 (11·8 [6·24-22·4]; both p<0·0001). Interpretation: Because the baseline kidney function of patients with renal cortical tumours is lower than previously thought, accurate assessment of kidney function is essential before surgery. Radical nephrectomy is a significant risk factor for the development of chronic kidney disease and might no longer be regarded as the gold standard treatment for small, renal cortical tumours.

UR - http://www.scopus.com/inward/record.url?scp=33747832155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747832155&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(06)70803-8

DO - 10.1016/S1470-2045(06)70803-8

M3 - Article

VL - 7

SP - 735

EP - 740

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 9

ER -